These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37767945)

  • 1. Combination therapy with kidney protective therapies: optimizing the benefits?
    Kotwal S; Perkovic E; Perkovic V
    Curr Opin Nephrol Hypertens; 2024 Jan; 33(1):136-143. PubMed ID: 37767945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.
    Yang Q; Lang Y; Yang W; Yang F; Yang J; Wu Y; Xiao X; Qin C; Zou Y; Zhao Y; Kang D; Liu F
    Diabetes Res Clin Pract; 2023 Apr; 198():110592. PubMed ID: 36842477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
    Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
    Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Tsukamoto S; Morita R; Yamada T; Urate S; Azushima K; Uneda K; Kobayashi R; Kanaoka T; Wakui H; Tamura K
    Diabetes Res Clin Pract; 2022 Dec; 194():110161. PubMed ID: 36403681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
    Lajara R
    Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients.
    Spasovski G; Rroji M; Hristov G; Bushljetikj O; Spahia N; Rambabova Bushletikj I
    Metab Syndr Relat Disord; 2024 Apr; 22(3):170-178. PubMed ID: 38386800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.
    Seksaria S; Dutta BJ; Kaur M; Gupta GD; Bodakhe SH; Singh A
    Curr Diabetes Rev; 2024; 20(6):e090823219597. PubMed ID: 37559236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CVOTs in primary and secondary prevention of kidney disease.
    De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
    Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.
    Rhee JJ; Han J; Montez-Rath ME; Chertow GM
    Diabetes Obes Metab; 2024 Apr; 26(4):1273-1281. PubMed ID: 38186297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
    Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
    Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
    Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.
    Cao H; Liu T; Wang L; Ji Q
    Diabetes Obes Metab; 2022 Aug; 24(8):1448-1457. PubMed ID: 35665989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
    Sarafidis P; Ferro CJ; Morales E; Ortiz A; Malyszko J; Hojs R; Khazim K; Ekart R; Valdivielso J; Fouque D; London GM; Massy Z; Ruggenenti P; Porrini E; Wiecek A; Zoccali C; Mallamaci F; Hornum M
    Nephrol Dial Transplant; 2019 Feb; 34(2):208-230. PubMed ID: 30753708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.